Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography

Swezey, Sarah F.; Giacomini, Kathleen M.; Abang, Anthony; Brass, Corstiaan; Stevens, David A.; Blaschke, Terrence F.

doi:10.1016/s0378-4347(00)80405-3

Cited by 30 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For CSF specimens from patients receiving intrathecal amphotericin B, amphotericin was excluded from the bioassay by the use of paper disks in lieu of agar wells (8). For CSF specimens from patients receiving intrathecal miconazole, ketoconazole concentrations were determined by a high-performance liquid chromatographic assay (14). This assay has been shown to give results indistinguishable from the bioassay at concentrations of ketocoriazole over the range found in CSF in this study (14).…”

Section: Methodsmentioning

confidence: 92%

“…For CSF specimens from patients receiving intrathecal miconazole, ketoconazole concentrations were determined by a high-performance liquid chromatographic assay (14). This assay has been shown to give results indistinguishable from the bioassay at concentrations of ketocoriazole over the range found in CSF in this study (14). This was reaffirmed in the present study by using standards prepared from CSF from patients without fungal disease and spiked with known amounts of ketoconazole; these standards were assayed concurrently by bioassay and high-performance liquid chromatography.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacology and toxicity of high-dose ketoconazole

Sugar

Alsip

Galgiani

et al. 1987

Antimicrob Agents Chemother

122

View full text Add to dashboard Cite

One hundred sixty patients were entered in two multicenter protocols to receive 400 to 2,000 mg of ketoconazole once daily for nonmeningeal or meningeal coccidioidomycosis. For 24 h after administration of all doses, mean concentrations in serum exceeded MICs for Coccidioides immitis (trough concentrations, >1 ,ug/ml). Mean peak concentrations occurred 4 to 6 h after administration, ranging from 7 to 17 ,ug/ml for doses of 400 to 2,000 mg. Incremental increases in peak concentrations in serum were greatest at doses of .1,200 mg. To investigate whether long-term therapy altered concentrations in serum, serial data were studied by several methods. The results suggested a trend to increased levels in serum with prolonged therapy, but were not statistically significant. All 168 cerebrospinal fluid (CSF) samples from meningitis patients contained c2.9,ig/ml, and only 6 contained >1 ,ug/ml.

show abstract

Section: Methodsmentioning

confidence: 92%

Section: Methodsmentioning

confidence: 99%

Pharmacology and toxicity of high-dose ketoconazole

Sugar

Alsip

Galgiani

et al. 1987

Antimicrob Agents Chemother

122

View full text Add to dashboard Cite

show abstract

“…The methanolic extract is evaporated to dryness at 45°C under a gentle stream of nitrogen. The residue is reconstituted in 200 μL methanol after ultrasonication, filtrated from 0.45 μm pore sized membrane filter, and injected into the chromatographic column (Swezey et al, 1982;Riley, 1986;Pietra et al, 1992;Velikinac et al, 2004). The drug serum levels were determined by HPLC method.…”

Section: Methodsmentioning

confidence: 99%

In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-β-cyclodextrin

2010

View full text Add to dashboard Cite

“…Quantitation of indinavir was based on a previously published high-pressure liquid chromatography (HPLC)-UV assay which was crossvalidated for human plasma (5). Plasma concentrations of ketoconazole and ciprofloxacin were determined by using validated HPLC assays with fluorescence detection; these assays were also based on previously published methods (22,23). Didanosine concentrations were measured by using a validated radioimmunoassay method (C. Knupp, B. Damle, P. Nichola, and S. Kaul, Abstr.…”

Section: Methodsmentioning

confidence: 99%

Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or Ciprofloxacin

Damle

Mummaneni

Kaul

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Didanosine formulation that contains a buffer to prevent it from acid-mediated degradation can result in a significant decrease in the oral absorption of certain drugs because of interactions with antacids. An enteric formulation of didanosine is unlikely to cause such drug interactions because it lacks antacids. This study was undertaken to determine whether the enteric bead formulation of didanosine (Videx EC) , 1.08), respectively. All three studies clearly indicated a lack of interaction. The T max and t 1/2 for indinavir, ketoconazole, and ciprofloxacin were similar between treatments. Our results showed that the lack of interaction of didanosine encapsulated enteric bead formulation with indinavir, ketoconazole, and ciprofloxacin indicates that this enteric formulation of didanosine can be concomitantly administered with drugs whose bioavailability is known to be reduced by interaction with antacids.

show abstract

Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography

Cited by 30 publications

References 6 publications

Pharmacology and toxicity of high-dose ketoconazole

Pharmacology and toxicity of high-dose ketoconazole

In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-β-cyclodextrin

Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or Ciprofloxacin

Contact Info

Product

Resources

About